Next Article in Journal
Demethoxycurcumin Suppresses Human Brain Glioblastoma Multiforme GBM 8401 Cell Xenograft Tumor in Nude Mice In Vivo
Next Article in Special Issue
Movement as a Positive Modulator of Aging
Previous Article in Journal
Achievements in Thermosensitive Gelling Systems for Rectal Administration
Previous Article in Special Issue
A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer
Article

Multiplex Autoantibody Detection in Patients with Autoimmune Polyglandular Syndromes

1
Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia
2
Endocrinology Research Centre, Ministry of Health of Russia, 117036 Moscow, Russia
*
Author to whom correspondence should be addressed.
Academic Editor: Martin Hill
Int. J. Mol. Sci. 2021, 22(11), 5502; https://doi.org/10.3390/ijms22115502
Received: 26 April 2021 / Revised: 18 May 2021 / Accepted: 20 May 2021 / Published: 23 May 2021
The diagnosis of autoimmune polyglandular syndrome (APS) types 1/2 is difficult due to their rarity and nonspecific clinical manifestations. APS-1 development can be identified with assays for autoantibodies against cytokines, and APS-2 development with organ-specific antibodies. In this study, a microarray-based multiplex assay was proposed for simultaneous detection of both organ-specific (anti-21-OH, anti-GAD-65, anti-IA2, anti-ICA, anti-TG, and anti-TPO) and APS-1-specific (anti-IFN-ω, anti-IFN-α-2a, and anti-IL-22) autoantibodies. Herein, 206 serum samples from adult patients with APS-1, APS-2, isolated autoimmune endocrine pathologies or non-autoimmune endocrine pathologies and from healthy donors were analyzed. The prevalence of autoantibodies differed among the groups of healthy donors and patients with non-, mono- and multi-endocrine diseases. APS-1 patients were characterized by the presence of at least two specific autoantibodies (specificity 99.5%, sensitivity 100%). Furthermore, in 16 of the 18 patients, the APS-1 assay revealed triple positivity for autoantibodies against IFN-ω, IFN-α-2a and IL-22 (specificity 100%, sensitivity 88.9%). No anti-cytokine autoantibodies were found in the group of patients with non-APS-1 polyendocrine autoimmunity. The accuracy of the microarray-based assay compared to ELISA for organ-specific autoantibodies was 88.8–97.6%. This multiplex assay can be part of the strategy for diagnosing and predicting the development of APS. View Full-Text
Keywords: autoimmune polyglandular syndrome; autoantibodies; microarray; multiplex assay autoimmune polyglandular syndrome; autoantibodies; microarray; multiplex assay
Show Figures

Figure 1

MDPI and ACS Style

Savvateeva, E.N.; Yukina, M.Y.; Nuralieva, N.F.; Filippova, M.A.; Gryadunov, D.A.; Troshina, E.A. Multiplex Autoantibody Detection in Patients with Autoimmune Polyglandular Syndromes. Int. J. Mol. Sci. 2021, 22, 5502. https://doi.org/10.3390/ijms22115502

AMA Style

Savvateeva EN, Yukina MY, Nuralieva NF, Filippova MA, Gryadunov DA, Troshina EA. Multiplex Autoantibody Detection in Patients with Autoimmune Polyglandular Syndromes. International Journal of Molecular Sciences. 2021; 22(11):5502. https://doi.org/10.3390/ijms22115502

Chicago/Turabian Style

Savvateeva, Elena N., Marina Y. Yukina, Nurana F. Nuralieva, Marina A. Filippova, Dmitry A. Gryadunov, and Ekaterina A. Troshina 2021. "Multiplex Autoantibody Detection in Patients with Autoimmune Polyglandular Syndromes" International Journal of Molecular Sciences 22, no. 11: 5502. https://doi.org/10.3390/ijms22115502

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop